Product Description
Mechanisms of Action: FFA1 Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Type 2 Diabetes|General Diabetes|Kidney Failure, Chronic|Other
Phase 2: General Diabetes|Type 2 Diabetes
Phase 1: Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| TAK-875_118 | P1 |
Completed |
Type 2 Diabetes |
2012-05-01 |
2024-06-06 |
Primary Endpoints |
|
| TAK-875_102 | P1 |
Completed |
Type 2 Diabetes |
2009-07-01 |
2024-06-06 |
||
| TAK-875_203 | P2 |
Terminated |
Type 2 Diabetes |
2014-01-01 |
2024-06-06 |
Primary Endpoints|Treatments |
|
| Fasiglifam 25 mg BID vs 50 mg QD | P2 |
Terminated |
Type 2 Diabetes |
2013-12-27 |
2022-03-13 |
Treatments |
|
| TAK-875_202 | P2 |
Completed |
Type 2 Diabetes |
2012-08-01 |
2024-06-06 |
Primary Endpoints|Treatments |
|
| TAK-875_201 | P2 |
Completed |
Type 2 Diabetes |
2010-09-01 |
2024-06-06 |
Primary Endpoints|Treatments |
|
| Comparison of TAK-875 to Glimepiride in Combination with Metformin in Subjects with Type II Diabetes | P3 |
Terminated |
Type 2 Diabetes |
2016-01-27 |
2022-03-13 |
Treatments |
|
| TAK-875_311 | P3 |
Withdrawn |
Kidney Failure, Chronic|Type 2 Diabetes |
2016-01-01 |
2024-06-06 |
Primary Endpoints|Treatments |
|
| TAK-875_306 | P3 |
Terminated |
Type 2 Diabetes |
2014-05-01 |
2024-06-06 |
Primary Endpoints|Treatments |
|
| TAK-875_304 | P3 |
Terminated |
Type 2 Diabetes |
2014-03-01 |
2024-06-06 |
Primary Endpoints|Treatments |
|
| TAK-875_310 | P3 |
Terminated |
Type 2 Diabetes |
2014-03-01 |
2024-06-06 |
Primary Endpoints |
|
| TAK-875_302 | P3 |
Terminated |
Type 2 Diabetes |
2014-03-01 |
2024-06-06 |
Primary Endpoints|Treatments |
|
| GRAND-307 | P3 |
Terminated |
Type 2 Diabetes |
2014-02-01 |
2024-06-06 |
Primary Endpoints|Treatments |
|
| TAK-875_309 | P3 |
Terminated |
Type 2 Diabetes |
2014-02-01 |
2024-06-06 |
Primary Endpoints|Treatments |
|
| TAK-875_303 | P3 |
Terminated |
Type 2 Diabetes |
2014-02-01 |
2024-06-06 |
Primary Endpoints|Treatments |
|
| Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Subjects With Type 2 Diabetes | P3 |
Terminated |
Type 2 Diabetes |
2013-12-27 |
2022-03-13 |
Treatments |
|
| 2011-001732-37 | P3 |
Terminated |
Type 2 Diabetes |
2013-12-27 |
2022-03-13 |
Treatments |
|
| 2011-001752-10 | P3 |
Terminated |
Type 2 Diabetes |
2013-12-27 |
2022-03-13 |
Treatments |
|
| 2013-000542-19 | P3 |
Terminated |
Type 2 Diabetes |
2013-12-27 |
2025-07-04 |
Treatments |
|
| TAK-875/OCT-002 | P3 |
Completed |
General Diabetes |
2013-12-01 |
2024-06-06 |
Primary Endpoints|Treatments |
|
| Comparison of TAK-875 with Placebo in Subjects with Type 2 Diabetes | P3 |
Completed |
Type 2 Diabetes |
2013-07-05 |
2022-03-13 |
Treatments |
|
| TAK-875_301 | P3 |
Completed |
Type 2 Diabetes |
2013-07-01 |
2024-06-06 |
Primary Endpoints|Treatments |
|
| TAK-875/CPH-030 | P3 |
Completed |
Other |
2012-12-01 |
2024-06-06 |
Primary Endpoints|Treatments |
|
| TAK-875/OCT-003 | P3 |
Completed |
General Diabetes |
2012-12-01 |
2024-06-06 |
Primary Endpoints|Treatments |
|
| TAK-875/CCT-003 | P3 |
Completed |
General Diabetes |
2012-09-01 |
2024-06-06 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/01/2024 |
PubMed |
Repurposing TAK875 as a novel STAT3 inhibitor for treating inflammatory bowel disease. |
|
07/31/2023 |
PubMed |
Oral administration of linoleic acid immediately before glucose load ameliorates postprandial hyperglycemia. |
|
05/30/2023 |
PubMed |
Molecular mechanism of fatty acid activation of FFAR1. |
|
06/22/2021 |
News Article |
Celon Pharma Files for Approval of Phase II Trial of CPL'280, a Second Generation GPR40 Agonist, in Type 2 Diabetes |
|
11/06/2019 |
News Article |
Liver-Chip Predicts Human Toxicity that was Undetected in Animal Studies for Drugs Halted in Clinical Trials |